Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been many oncology drug approvals. Over time, the number of approvals decreased each year.
Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been good number of oncology drug approvals. Over time, number of approvals each year have dropped down from 22, to 19 and so on.
As of 2023, there's only been two drugs approved, Tancredi sees that "there could be three or four drugs approved before the end of this year, maybe more." There's a number of products in the pipeline that could get approved this year.
"So when it's all said and done at the end of 2023, you know, we could be in double digits again, for as far as approvals are concerned," he added.